As we approach a new week for the stock market, we will see if the overall markets can rebound from last weeks performance. Last week marked the worst week in 2 years for the stock market in terms of overall sell offs. World futures as of 8:00PM CST are all up (green) right now potentially signaling a solid Monday trading session. It's too early to tell, but we always enjoy looking at futures to get some what of an idea looking forward.
$PPT - Target price @ 5.20 in our opinion. Despite overall market sell offs last week, PPT still managed to have a solid week. We are watching for a potential 5.20 break. IF so, we could see additional upward momentum. MACD and RSI are both setting up really nice here in our opinion.
$DHT - Target price @ $3.65 in our opinion. We could see upward momentum building IF the stock can power through 3.65 resistance. Moving averages are sitting around the 3.70 range, so we could see those levels if resistance is broken through. With the way the MACD is setting up, it does come across as a pretty appealing chart and one we will definitely watch Monday.
$NSU - Target price @ 2.19 in our opinion. We will follow the chart and see if the stock can power through 2.19 resistance levels. The stock has been coming out of oversold (RSI) territory and may be heating up towards those moving averages. We are also coming across a potential MACD crossover that could be bullish in our opinion.
$TROV - Target price level @ 0.44 in our opinion. As you can see from the chart, the stock was up significantly on Friday +24.4%. IF the stock can break .44, it could be setting up a huge gap up in our opinion. You could argue that a .44 break could be signaling a run to .50-.60 territories. The catalyst Friday was company news in regards to trials. You can see a quote from Newswire below.
TrovaGene (TROV) said on Friday encouraging preclinical data was shown by the synergy of PCM-075 with Johnson & Johnson's (JNJ) Zytiga for prostate cancer cell lines, adding that the data was presented at the 2018 Genitourinary Cancers Symposium in San Francisco, California.
Comments